Related Experiment Video
Updated: Jan 16, 2026
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Effectiveness of Beta-Blockers in Reducing Mortality and Recurrence After Myocardial Infarction: A Systematic Review
Alaa M Popraya1, Muhammad Ibrahim2, Nouman Anthony3
1Acute Medicine, Royal Derby Hospital, Derby, GBR.
Insights
Beta-blockers significantly reduce mortality and recurrent heart attacks (MI) in patients after myocardial infarction. These findings support their continued use in post-MI care, especially for those with reduced heart function.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Beta-blockers are a traditional treatment for myocardial infarction (MI) recovery.
- Their role alongside modern cardiac interventions is under ongoing evaluation.
Purpose of the Study:
- To systematically review the effectiveness of beta-blockers in reducing mortality and cardiovascular events post-MI.
- To assess beta-blocker efficacy across diverse patient populations and clinical settings.
Main Methods:
- Systematic review of studies from 1983-2014 using PubMed, Embase, Scopus, and CENTRAL.
- Inclusion of 4 studies (2 RCTs, 1 post hoc analysis, 1 observational study) with 19,078 participants.
Main Results:
- Beta-blocker therapy consistently reduced all-cause mortality, cardiovascular mortality, and recurrent MI.
- A 23-26% reduction in overall mortality and up to 41% reduction in recurrent MI were observed.
- Benefits were most pronounced in patients with reduced left ventricular function.
Conclusions:
- Findings support the continued use of beta-blockers in post-MI management.
- Individualized treatment approaches are necessary due to study heterogeneity.
- Results align with major cardiology guidelines, reaffirming beta-blocker relevance.
Abstract:
Beta-blockers have traditionally been a mainstay in the management of patients recovering from myocardial infarction (MI). However, their role in the era of modern cardiac interventions remains a topic of active discussion. This systematic review evaluated evidence from 1983 to 2014, drawn from PubMed, Embase, Scopus, and CENTRAL, on the effectiveness of beta-blockers in reducing mortality and recurrent cardiovascular events in adults following MI. After a comprehensive screening process, four eligible studies (two randomized controlled trials, one post hoc analysis, and one observational study) were included, encompassing a total of 19,078 participants with varied clinical settings and patient profiles. Across these studies, beta-blocker therapy was consistently associated with reductions in all-cause mortality, cardiovascular mortality, and recurrent MI, particularly among individuals with reduced left ventricular function. Some benefit was also observed in those with preserved function, though with less consistency. The magnitude of benefit included a 23-26% reduction in overall mortality and up to a 41% reduction in recurrent MI. Despite differences in study design, patient characteristics, and treatment protocols, the overall findings support the continued use of beta-blockers in post-infarction care. Limitations included heterogeneity in populations, beta-blocker regimens, and study eras, highlighting the need for individualized treatment approaches. Nonetheless, these results align with current guidelines from the American College of Cardiology/American Heart Association and the European Society of Cardiology, reaffirming the relevance of beta-blockers in improving outcomes in this patient population.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:28Antihypertensive Drugs: Types of β-Blockers
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers